Chemomab Therapeutics Ltd Share Price Today: Live Updates & Key Insights

Chemomab Therapeutics Ltd share price today is $1.37, up -2.86%. The stock opened at $1.39 against the previous close of $1.4, with an intraday high of $1.39 and low of $1.37.

Chemomab Therapeutics Ltd Share Price Chart

Chemomab Therapeutics Ltd

us-stock
To Invest in {{usstockname}}
us-stock

Chemomab Therapeutics Ltd Share Price Performance

$1.37 -0.0286(-2.86%) CMMB at 27 Jul 2026 02:28 PM Biotechnology
Lowest Today 1.37
Highest Today 1.39
Today’s Open 1.39
Prev. Close 1.4
52 Week High 4.80
52 Week Low 1.35
Day’s Range: Low 1.37 High 1.39
52-Week Range: Low 1.35 High 4.80
1 day return -
1 Week return -7.69
1 month return -14.81
3 month return -7.38
6 month return -20.46
1 year return +24.32
3 year return +8.66
5 year return -92.08
10 year return -

Chemomab Therapeutics Ltd Institutional Holdings

HBM Healthcare Investments AG Ord 2.13

Advisory Services Network, LLC 0.00

Chemomab Therapeutics Ltd Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Chemomab Therapeutics Ltd Fundamentals

Market Cap 10.26 M

PB Ratio 0.9695

PE Ratio 0.0

Enterprise Value 0.11 M

Total Assets 13.81 M

Volume 42393

Chemomab Therapeutics Ltd Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-66827 -0.1M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-24158586 -24.2M, FY22:-27646000 -27.6M, FY21:-12555000 -12.6M, FY20:-5930000 -5.9M, FY19:27124000 27.1M

Quarterly Revenue Q1/2026:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q1/2026:null 0.0M, Q3/2025:null 0.0M, Q2/2025:-33687 -0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M

Quarterly Net worth Q1/2026:-1773000 -1.8M, Q3/2025:-1742000 -1.7M, Q2/2025:-2057000 -2.1M, Q1/2025:-3323000 -3.3M, Q3/2024:-3483000 -3.5M

About Chemomab Therapeutics Ltd & investment objective

Company Information Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO Dr. Adi Mor George Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Chemomab Therapeutics Ltd FAQs

What is the share price of Chemomab Therapeutics Ltd today?

The current share price of Chemomab Therapeutics Ltd is $1.37.

Can I buy Chemomab Therapeutics Ltd shares in India?

Yes, Indian investors can buy Chemomab Therapeutics Ltd shares by opening an international trading and demat account with Motilal Oswal.

How to buy Chemomab Therapeutics Ltd shares in India?

You can easily invest in Chemomab Therapeutics Ltd shares from India by:

Can I buy fractional shares of Chemomab Therapeutics Ltd?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Chemomab Therapeutics Ltd?

Chemomab Therapeutics Ltd has a market cap of $10.26 M.

In which sector does Chemomab Therapeutics Ltd belong?

Chemomab Therapeutics Ltd operates in the Biotechnology sector.

What documents are required to invest in Chemomab Therapeutics Ltd stocks?

To invest, you typically need:

What is the PE and PB ratio of Chemomab Therapeutics Ltd?

The PE ratio of Chemomab Therapeutics Ltd is N/A and the PB ratio is 0.97.